← Browse by Condition
Medical Condition
metastatic hormone sensitive prostate cancer
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2
NCT05818683 Phase 1
Recruiting
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Enrollment
277 pts
Location
United States, Austr...
Sponsor
Janssen Research & Development...
NCT06991556 Phase 2
Recruiting
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Enrollment
150 pts
Location
United States, Austr...
Sponsor
Novartis Pharmaceuticals
NCT07339267 Phase 1
Recruiting
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
Enrollment
12 pts
Location
China
Sponsor
Astellas Pharma Global Develop...